News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
MYX Finance Price Is Skyrocketing — Will The Rally Continue?
MYX Finance’s token soared nearly 30% in a day, but weakening demand and bearish divergences suggest the rally may soon lose steam.
BeInCrypto·2025/09/27 03:48
Circle Unveils Refund Protocol to Tackle Blockchain Disputes
Cryptotale·2025/09/27 02:48
Two Nasdaq-Listed Firms Add Toncoin (TON) to Reserves, Could Face Pressure as Token and Shares Slide
Coinotag·2025/09/27 02:12
Hester Peirce Says She May Advocate More Crypto-Friendly Policy, Hints at NFT Plans Post-SEC
Coinotag·2025/09/27 02:12
Stellar (XLM) Tests Key $0.32 Support, Could Target $0.50 Resistance as USDY Joins Network
Coinotag·2025/09/27 02:12
Chainlink Could See Breakout as Whales Accumulate and Bullish Pennant Holds in Demand Zone
Coinotag·2025/09/27 02:12
XRP Holds $2.74 Support as Traders Weigh Moves Toward $3.20 or $2.20
Cryptonewsland·2025/09/27 01:54
Pepe Coin Eyes 109% Rally as Price Consolidates in Apex Zone
Cryptonewsland·2025/09/27 01:54
Flash
12:56
Spot Gold Drops $14 in Short-Term Spot gold has fallen $14 in the short term, declining over 1.00% during the day, currently reported at $4133.10 per ounce. (Jin Shi)
12:51
Vivos (OTC market code: RDGL) has received Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) and will initiate a human clinical feasibility study of its Radiogel® Precision Radionuclide Therapy™.This approval marks a key step forward for the clinical application of this innovative therapy, allowing the company to begin initial safety and feasibility assessments in humans. The Radiogel® technology is designed to enable precise radiation treatment within tumors and is expected to provide a new treatment option for cancer patients. The approved clinical study will collect essential data to lay the foundation for larger-scale clinical trials in the future.
12:51
Anixa Biosciences announced that in its clinical trial of CAR-T cell therapy, no dose-limiting toxicities were observed up to the previously established 3x10⁶/kg dose level.This positive safety data lays the foundation for further exploration of higher doses and demonstrates the potential of this therapy in terms of patient tolerability.
News